



STANDARDIZED ONE PAGE PHARMACY PRIOR AUTHORIZATION FORM

Mississippi Division of Medicaid, Pharmacy Prior Authorization Unit, Gainwell Technologies, PO Box 2480, Ridgeland, MS 39158

Medicaid Fee for Service/MSCAN/MSCHIP Members
Gainwell Technologies

Fax to: 1-866-644-6147 Ph: 1-833-660-2402

[Pharmacy Prior Authorization - Mississippi Division of Medicaid \(ms.gov\)](http://ms.gov)

Submit your PA requests via the MESA (Medicaid Enterprise System Assistance) provider portal for the most efficient processing
[Mississippi Medical Assistance Portal for Providers > Home \(ms-medicaid-mesa.com\)](http://ms-medicaid-mesa.com)

BENEFICIARY INFORMATION	
Beneficiary ID: _____ - _____ - _____	DOB: _____ / _____ / _____
Beneficiary Full Name: _____	
PRESCRIBER INFORMATION	
Prescriber's NPI: _____	
Prescriber's Full Name: _____	Phone: _____
Prescriber's Address: _____	FAX: _____
PHARMACY INFORMATION	
Pharmacy NPI: _____	
Pharmacy Name: _____	
Pharmacy Phone: _____	Pharmacy FAX: _____
CLINICAL INFORMATION	
Requested PA Start Date: _____ Requested PA End Date: _____	
Drug/Product Requested: _____ Strength: _____ Quantity: _____	
Days Supply: _____ RX Refills: _____ Diagnosis or ICD-10 Code(s): _____	
<input type="checkbox"/> Hospital Discharge <input type="checkbox"/> Additional Medical Justification Attached	
Medications received through coupons and/or samples are not acceptable as justification	
PLEASE COMPLETE AND FAX DRUG SPECIFIC CRITERIA/ADDITIONAL DOCUMENTATION FORM FOUND BELOW	
<i>Prescribing provider's signature (signature and date stamps, or the signature of anyone other than the provider, are not acceptable)</i>	
I certify that all information provided is accurate and appropriately documented in the patient's medical chart.	
Signature required: _____	Date: _____
Printed name of prescribing provider: _____	

FAX THIS PAGE



2023-24 Mississippi Division of Medicaid Synagis® Prior Authorization Criteria*

NOTE: With FDA approval of nirsevimab (Beyfortus), Synagis should only be administered if Beyfortus is not available. PA approval in such cases will be limited to children meeting these criteria.

Beneficiaries must meet at least one of the bullet point criteria for age at time of request.

Age ≤ 1 year at start of RSV season and one of the following:

- Prematurity of ≤ 28 weeks 6 days gestation
- Documentation of **chronic lung disease (CLD)** of prematurity (defined as gestational age of 29 weeks 0 days – 31 weeks 6 days **AND** requirement for > 21% oxygen or chronic ventilator therapy for at least the first 28 days after birth).
Documentation of **hemodynamically significant congenital heart disease (CHD)** **AND** one of the following:
 1. **acyanotic heart disease** receiving medication for congestive heart failure **AND** will require cardiac surgery
 2. **moderate to severe pulmonary hypertension**
 3. documentation of **cyanotic heart disease** through consultation with pediatric cardiologist
- Documentation of **congenital abnormalities of the airway OR neuromuscular disease** that impairs the ability to clear secretions from the upper airway because of ineffective cough
- Documentation of **cystic fibrosis AND** clinical evidence of CLD (defined as gestational age of 29 weeks 0 days – 31 weeks 6 days **AND** requirement for oxygen >21% for at least the first 28 days after birth) **OR** nutritional compromise
- Documentation of **profound immunocompromise** (includes, but is not limited to, patients undergoing stem cell transplantation, chemotherapy) during the RSV season

Age 12 – 24 months at start of RSV season and one of the following:

- Documentation of **chronic lung disease (CLD)** of prematurity (defined as gestational age ≤ 31 weeks 6 days **AND** requirement for > 21% oxygen or chronic ventilator therapy for at least the first 28 days after birth) **AND** required continued medical support (defined as chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen during the 6-month period before the RSV season).
- Documentation of **cystic fibrosis AND** one of the following:
 1. manifestations of **severe lung disease** (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persists when stable)
 2. weight for length < 10th percentile
- Documentation of **profound immunocompromise** (includes, but is not limited to, patients undergoing stem cell transplantation, chemotherapy, or organ transplants) during the RSV season.

Coverage limitations:

- Beyfortus (nirsevimab) is approved for prevention of RSV in newborns and infants in their first RSV season or children 24 months of age or younger who are at risk of severe RSV disease in their second season.
- Per FDA labeling, children who have received Beyfortus should not receive Synagis for the same RSV season.
- If Synagis was administered initially for the season and fewer than 5 doses were administered, the infant should receive 1 dose of Beyfortus. No further Synagis should be administered.
- If Synagis was administered in season 1 and the child is eligible for RSV prophylaxis in season 2, the child should receive Beyfortus in season 2, if available. If Beyfortus is not available, Synagis should be administered as previously recommended.
- Synagis PAs will only be approved for one month at a time, and only if Beyfortus supply is limited.
- Subject to limitations above, PA requests for Synagis will be approved (one month at a time) starting at the onset of RSV season for a maximum of up to 5 doses and a dosing interval not less than 30 days between injections. PA requests will be accepted starting **Wednesday, October 11, 2023**, for dates of service starting **Wednesday, November 1, 2023**.
- Synagis® will **NOT** be authorized for administration prior to November 1, 2023; this refers to the typical season and excludes off-season case-by-case authorizations. Synagis® dosing authorizations will extend for the recommended number of doses OR until the end of epidemic RSV season as defined by CDC - whichever occurs first. Monthly prophylaxis should be discontinued for any infant or young child who experiences a breakthrough RSV hospitalization.

NOTE:

- Prophylaxis in infants with Down Syndrome is not recommended without the presence of one of the criteria listed above.

* American Academy of Pediatric Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*. Available at <http://pediatrics.aappublicaions.org/content/early/2014/07/23/peds.2014-1665>.

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM. **Confidentiality Notice:** This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-833-660-2402) or fax (1-866-644-6147) and destroy all copies of the original message. 7/11/2024

CRITERIA/ADDITIONAL DOCUMENTATION

RSV-SYNAGIS 2023-24



BENEFICIARY INFORMATION

Beneficiary ID: _____ - _____ - _____ DOB: ____/____/____

Beneficiary Full Name: _____

RSV-SYNAGIS® CRITERIA/ADDITIONAL DOCUMENTATION*

PA requests will be accepted starting **October 11, 2023**, for dates of service starting **November 1, 2023**.

For the typical RSV season, PA requests will be approved (one month at a time) starting at the onset of RSV season on November 1, 2023 for a maximum of up to 5 doses, given monthly, per RSV season. A dosing interval *not less than 30 days* between injections is suggested. Synagis® dosing authorizations will extend for the recommended number of doses *OR* until the end of epidemic RSV season as defined by CDC and/or in consultation with pediatric providers - *whichever occurs first*. DOM will notify providers when the end of the RSV season is determined.

PA REQUEST INFORMATION:

PHARMACY INFORMATION – Synagis® is available through a limited distribution network established by the manufacturer.

Synagis Dosing Regimen: 15mg/kg IM once a month Product Availability: single dose vial: 50mg/0.5ml, 100mg/1 ml

Birth Date: _____ Gestational Age: ____ weeks: ____ days: ____ Birth Weight: ____ lbs. ____ oz.

NDC#: _____ Current Weight: ____ lbs. ____ oz. Date last weighed: _____

Has the patient received a dose of Beyfortus (nirsevimab)? Yes ___ No ___ If “Yes”, list date of administration: _____

Did the patient receive Synagis in the hospital? Yes ___ No ___ If “Yes”, list date(s) of administration: _____

Can the provider supply and administer Beyfortus? Yes ___ No ___ If “No”, please provide an explanation: _____

Has the patient been hospitalized due to RSV at any time since May 1, 2023? Yes _____ No _____

Monthly prophylaxis should be discontinued for any infant or young child who experiences a breakthrough RSV hospitalization.

Check the criteria used to qualify the patient for Synagis®. All information requested on PA form must be completed for approval consideration.

<p>Age ≤ 1 year at start of RSV season and one of the following:</p>	<p>Age 12 – 24 months at start of RSV season and one of the following:</p>
<ul style="list-style-type: none"> <input type="radio"/> Prematurity of ≤ 28 weeks 6 days gestation. <input type="radio"/> Documentation of chronic lung disease (CLD) of prematurity*. <input type="radio"/> Documentation of hemodynamically significant CHD AND one of the following: <ol style="list-style-type: none"> (1) Acyanotic heart disease receiving medication for congestive heart failure AND will require cardiac surgery. (2) Moderate to severe pulmonary hypertension. (3) Documentation of cyanotic heart disease through consultation with pediatric cardiologist. <input type="radio"/> Documentation of congenital abnormalities of the airway OR neuromuscular disease that impairs the ability to clear secretions from the upper airway because of ineffective cough. <input type="radio"/> Documentation of cystic fibrosis AND clinical evidence of CLD of prematurity* OR nutritional compromise. <input type="radio"/> Documentation of being profoundly immunocompromised** during the RSV season. 	<ul style="list-style-type: none"> <input type="radio"/> Documentation of chronic lung disease (CLD) of prematurity* AND required continued medical support** during the 6-month period before the RSV season. <input type="radio"/> Documentation of cystic fibrosis AND one of the following: <ol style="list-style-type: none"> (1) Manifestations of severe lung disease**. (2) Weight for length < 10th percentile. <input type="radio"/> Documentation of being profoundly immunocompromised** during the RSV season.

* **Chronic lung disease of prematurity defined as gestational age ≤ 31 weeks 6 days AND requirement for oxygen >21% or chronic ventilator therapy for at least the first 28 days after birth.** ** **Refer to 2023-24 Division of Medicaid Synagis® PA Criteria Instructions for more detailed definitions. Reference: Pediatrics 2014:134; 415 originally published online July 28, 2014.**

FAX THIS PAGE